Stay updated with breaking news from Ar T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.
Developed by ImmunoAct, IIT Bombay and Tata Memorial Hospital, the therapy has been administered to 15 patients in India. Three of them have successfully achieved cancer remission. Dr Gupta, the first commercial patient to be declared free of cancer, speaks of his experience exclusively to The Indian Express
Upon hearing the phrase ‘cancer treatment’, the first word that can typically spring to mind is chemotherapy – a primary therapy which uses powerful chemicals to destroy rapidly growing cancer cells in the body.
The FDA suggests people participating in clinical trials with these therapies are monitored for the rest of their lives for any new cancerous cells.
Two months after announcing an inquiry into reports of new cancers in patients treated with CAR T-cell therapies, the FDA is directing makers of these therapies to add new safety warnings to product labels describing this risk. Companies have 30 calendar days to comply.